[1] DAVIS F G, DOLECEK T A, McCARTHY B J,et al. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data[J].Neuro Oncology,2012,14(9):1171-1177.
[2] 石远凯,孙燕,于金明,等.中国肺癌脑转移专家共识(2017版)[J].中国肺癌杂志,2017,20(1):1-12.
[3] TAILLIBERT S, Le RHUN É.Epidemiology of brain metastases[J]. Cancer Radiother,2015,19(1): 3-9.
[4] SHOLL L M.Biomarkers in lung adenocarcinoma:a decade of progress[J]. Arch Pathol Lab Med, 2015, 139(4):469-480.
[5] HYNES N E, LANE H A.ERBB receptors and cancer: the complexity of targeted Inhibitors[J].Nature Rev Cancer,2005,5(7):341-344.
[6] VLAHOVIC G, CRAWFORD J.Activation of tyrosine kinases in cancer[J]. Oncologist,2003,8(6): 531-538.
[7] BASELGA J.Why the epidermal growth factor receptor? The rationale for cancer therapy[J]. Oncologist,2002,7(suppl 4):2-8.
[8] MENDELSOHN J.Targeting the epidermal growth factor receptor for cancer therapy[J].J Clin Oncol,2002,20(18 Suppl):1-13S.
[9] HEON S,YEAP B Y, LINDEMAN N I,et al.The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations[J]. Clin Cancer Res,2012,18(16):4406-4414.
[10] ZENG Y D,LIAO H,QIN T,et al.Blood-brain barrier permeability of gefitinib inpatients withbrain metastases from non-small-celllung cancer before and during whole brain radiation therapy[J].Oncotarget,2015,6(10): 8366-8376.
[11] EICHLER A F, KAHLE K T, WANG D L, et al.EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer[J]. Neuro Oncol,2010,12(11):1193-1199.
[12] PORTA R,SÁNCHEZ-TORRES J M,PAZ-ARES L,et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation[J].Eur Respir J, 2011,37(3):624-631.
[13] PIETRAS K,OSTMAN A.Hallmarks of cancer: interactions with the tumor stroma[J].Exp Cell Res,2010, 316(8): 1324-1331.
[14] QIAN B Z, POLLARD J W.Macrophage diversity enhances tumor progression and metastasis[J]. Cell, 2010, 141(1):39-51.
[15] IUCHI T, SHINGYOJI M, SAKAIDA T,et al.Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma[J]. Lung Cancer,2013,82(2):282-287.
[16] PESCE G A, KLINGBIEL D, RIBI K,et al.Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)[J]. Eur J Cancer,2012,48(3):377-384.
[17] Seike T, Fujita K, Yamakawa Y, et al.Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis[J].Clin Exp Metastasis,2011,28(1):13-25.
[18] REID H, RAHUL J.The role of the neural niche in brain metastasis[J]. Clin Exp Metastasis,2017,34:369-376.
[19] TOGASHI Y, MASAGO K, FUKUDO M,et al.Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer[J].J Thorac Oncol,2010,5(7):950-955.
[20] DENG Y, FENG W, WU J,et al.The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer[J].Mol Clin Oncol,2014,2(1):116-120.
[21] WEBER B, WINTERDAHL M, MEMON A,et al.Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor[J].J Thorac Oncol,2011,6(7): 1287-1289.
[22] OLMEZ I,DONAHUE B R,BUTLER J S,et al.Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis[J].Lung Cancer,2010,70(2):174-179.
[23] SPERDUTO P W, KASED N, ROBERGE D, et al.Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases[J].J Clin Oncol,2011,30(4):419-425.
[24] LIND J S, LAGERWAARD F J, SMIT E F,et al.Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2009,74(5):1391-1396.
[25] LEE S M, LEWANSKI C R, COUNSELL N,et al.Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases[J]. J Natl Cancer Inst,2014,106(7):1.
[26] WELSH J W,KOMAKI R,AMINI A,et al.Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer[J].J Clin Oncol,2013,31(7):895-902.
[27] CHMIELECKI J,FOO J,OXNARD G R,et al.Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling[J].Sci Transl Med,2011,3(90):90ra59.
[28] HUGHES A N, O’BRIEN M E, PETTY W J, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating
[29] erlotinib dose in current smokers[J].J Clin Oncol,2009,27(8):1220-1226.
[30] ZHOU L, HE J Z, XIONG W J,et al.Impact of whole brain radiation therapy on CSF penetration ability of icotinib in EGFR-mutanted non-small cell lung cancer patients with brain metastases: results of phase I dose-escalation study[J].Lung Cancer,2016,96(6):93-100.
[31] SHI Y K, ZHANG L, LIU X Q,et al.Icotinib: kick-starting the Chinese anticancer drug industry[J].Lancet Oncol,2013,14(10):953-961.
[32] YANG J J,ZHOU C,HUANG Y,et al.Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial[J].Lancet Respir Med,2017,5(9): 707-716.
[33] SCHULER M, WU Y L, HIRSH V, et al.First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases[J].J Thorac Oncol,2016,11(3):380-390.
[34] KASHIMA J,OKUMA Y,MIWA M,et al.Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors[J].Med Oncol,2016,33(11):129-132.
[35] PARK S J,KIM H T,LEE D H,et al.Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation[J]. Lung Cancer,2012,77(3):556-560.
[36] PARK K, TAN EH, O’BYRNE K,et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase II, open-label, randomised controlled trial[J].Lancet Oncol,2016,17(5):577-589.
[37] HOFFKNECHT P, TUFMAN A, WEHLER T,et al.Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease[J].J Thorac Oncol,2015,10(1):156-163.
[38] MOK TS,WU YL,AHN MJ,et al,Osimertinib or platinum-
[39] pemetrexed in EGFRT790- positive lung cancer[J].N Engl J Med,2017,376(7):629-640
[40] REUNGWETWATTANA T,NAKAGAWA K,CHO B C,et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer[J]. J Clin Oncol,2018,28:JCO2018783118. |
